POSB43 Budget Impact Analysis of Venetoclax for Management of Acute Myeloid Leukemia from the Perspective of the Social Security and the Private Sector in Argentina

PALACIOS, A; ESPINOLA, N; GONZALEZ, JM; RIVAS, MM; ROJAS-ROQUE, C; KANEVSKY, D; MORISSET, P; AUGUSTOVSKI, F; PICHON-RIVIERE, DA; BARDACH, A

VALUE IN HEALTH

WILEY-BLACKWELL PUBLISHING, INC

Año: 2022 vol. 25

1098-3015

ObjectivesThis study aimed to estimate the budget impact of venetoclax incorporation for treatment of patients with acute myeloid leukemia (AML) (a rare disease) over 65 years of age or those with comorbidities contraindication for the use of intensive chemotherapy, from the perspective of the social security and the private healthcare sector in Argentina.MethodsA budget impact model was programmed to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax in combination) for a third-party payer over three years. Input parameters were obtained from a literature review, complemented by expert opinion using the modified Delphi method. Healthcare costs were estimated by the microcosting approach in September 2020. A one-way sensitivity analysis was conducted.ResultsThe incidence of AML in people over 65 years was estimated at 20.1 cases per 100,000 individuals-year. For a cohort of 1,000,000 individuals covered by a social security third-party payer (with 20% of its population over 65 years of age), incorporating venetoclax implied an average absolute budget impact per year of ARS 11,927,006 (USD 157,671) and an average budget impact per member per month (PMPM) of ARS 0.99 (USD 0.013). For the private sector third-party payer (with 5% of its population over 65 years of age), incorporating venetoclax implied an average absolute budget impact per year of ARS 1,390,368 (USD 18,380) and an average budget impact PMPM of ARS 0.12 (USD 0.002). The duration of treatment with venetoclax was the most influential parameter in the budget impact Results:ConclusionsThe incorporation of venetoclax was associated with a slight cost increase in the social security and the private sector in Argentina, with the extended treatment duration being the most influential factor.